Skip to main content

Zinbryta Dosage

Generic name: Daclizumab 150mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors

Medically reviewed by Last updated on Jul 7, 2023.

Dosing Information

The recommended dosage of ZINBRYTA is 150 milligrams injected subcutaneously once monthly [see Dosage and Administration (2.3, 2.4)].

Instruct patients to inject a missed dose as soon as possible but no more than two weeks late. After two weeks, skip the missed dose and take the next dose on schedule. Administer only one dose at a time.

Important Administration Instructions

ZINBRYTA is for subcutaneous use only.

Train patients in the proper technique for self-administering subcutaneous injections using the prefilled autoinjector or syringe.

Thirty minutes prior to injection, remove ZINBRYTA from the refrigerator to allow the drug to warm to room temperature. Do not use external heat sources such as hot water to warm ZINBRYTA. Do not place ZINBRYTA back into the refrigerator after allowing it to warm to room temperature [see How Supplied/Storage and Handling (16.2)].

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ZINBRYTA is a colorless to slightly yellow, clear to slightly opalescent solution. Do not use ZINBRYTA if it is cloudy or there are visible particles.

Sites for injection include the thigh, abdomen, and back of the upper arm.

Use each prefilled autoinjector or syringe one time and then place in a sharps disposal container for disposal according to community guidelines [see How Supplied/Storage and Handling (16.3)].

Assessment Prior to Initiating ZINBRYTA

Hepatic Assessment

Prior to initiating ZINBRYTA, obtain and evaluate the following:

  • Serum transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and total bilirubin levels. Initiation of ZINBRYTA is contraindicated in patients with pre-existing hepatic disease or hepatic impairment including ALT or AST at least 2 times the ULN [see Contraindications (4) and Warnings and Precautions (5.1)].

Assessment for Tuberculosis and Other Infections

  • Evaluate patients at high risk for tuberculosis infection prior to initiating treatment with ZINBRYTA [see Warnings and Precautions (5.5)]. For patients testing positive for tuberculosis, treat tuberculosis by standard medical practice prior to therapy with ZINBRYTA.
  • Avoid initiating ZINBRYTA in patients with tuberculosis or other severe active infection [see Warnings and Precautions (5.5)].
  • Prior to initiation of ZINBRYTA, screen patients for Hepatitis B and C. ZINBRYTA is contraindicated in patients with pre-existing hepatic disease [see Contraindications (4)].


Because vaccination with live vaccines is not recommended during treatment and up to 4 months after discontinuation of treatment, consider any necessary immunization with live vaccines prior to treatment with ZINBRYTA [see Warnings and Precautions (5.5)].

Laboratory Testing and Monitoring to Assess Safety after Initiating ZINBRYTA

Conduct the following laboratory tests at periodic intervals to monitor for early signs of potentially serious adverse effects:

Liver Tests

Test transaminase levels and total bilirubin monthly and assess before the next dose of ZINBRYTA. Follow transaminase levels and total bilirubin monthly for 6 months after the last dose of ZINBRYTA. As shown in Table 1, interruption or discontinuation of ZINBRYTA therapy is recommended for management of certain liver test abnormalities [see Warnings and Precautions (5.1)].

Table 1: ZINBRYTA Treatment Modification for Liver Test Abnormalities
Elevated Transaminases and/or Total Bilirubin
[see Warnings and Precautions (5.1)]
Lab Value(s) Recommendations
ALT or AST greater than 5 times ULN

Total bilirubin greater than 2 times ULN

ALT or AST greater than or equal to 3 but less than 5 times ULN and total bilirubin greater than 1.5 but less than 2 times ULN
  • Interrupt ZINBRYTA therapy and investigate for other etiologies of abnormal lab value(s).
  • If no other etiologies are identified, then discontinue ZINBRYTA.
  • If other etiologies are identified, re-assess the overall risk-benefit profile of ZINBRYTA in the patient and consider whether to resume ZINBRYTA when both AST or ALT are less than 2 times ULN and total bilirubin is less than or equal to ULN.

In clinical trials, permanent discontinuation of therapy was required if the patient had liver test abnormalities resulting in suspension of study treatment for at least 8 consecutive weeks.

ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.